Effects of ivabradine on 6-minute walk test and quality of life in patients with previously implanted CRT-D

Journal of Investigative Medicine

Volumn 61, Issue 6, 2013, Pages 1013-1017

  Ates, Ismail ^a   Yavuz, Asuman H ^b   Doǧru, Mehmet ^a   Genç, Ahmet ^a   Ulucan, Şeref ^c   Sarikaya, Metin ^d   Çetinkaya, Ramazan ^d   Keser, Ahmet ^c   Akpek, Mahmut ^e   Kaya, Mehmet G ^e  

^a Medline Antalya Private Hospital   (Turkey)

^b MEDICAL PARK HOSPITAL   (Turkey)

^c MEVLANA UNIVERSITY   (Turkey)

^d Antalya Research and Education Hospital ^*  (Turkey)

^e ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Ischemic heart failure; Ivabradine; Quality of life

Indexed keywords

IVABRADINE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FUROSEMIDE; SPIRONOLACTONE;

6 MINUTE WALK TEST; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; EXERCISE TEST; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC HEART FAILURE; MALE; MINNESOTA LIFE QUALITY TEST; NEW YORK HEART ASSOCIATION CLASS; QUALITY OF LIFE; RESTING HEART RATE; SCORING SYSTEM; SINUS RHYTHM; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WALKING; BRADYCARDIA; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; ECHOCARDIOGRAPHY; EXERCISE; HEART RATE MEASUREMENT; LABORATORY TEST; MAXIMUM TOLERATED DOSE; SIX MINUTE WALK TEST; TREATMENT DURATION;

AGED; BENZAZEPINES; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84888343870     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31829614f0     Document Type: Article

References (32)

1. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004;25:1614-1619.
2. Davies M, Hobbs F, Davis R, et al. Prevalence of left ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439-444.
3. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction Vpharmacological approaches. J Card Fail. 1999;5:357-382.
4. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation. 1994;90:644-645.
5. Gwadry-Sridhar FH, Flintoft V, Lee DS, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med. 2004;164: 2315-2320.
6. Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;4:486-491.
7. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-894.
8. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817-821.
9. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459.
10. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
11. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 2006;27:2682-2688.
12. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289: 730-740.
13. McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141:381-390.
14. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;9:1280-1284.
15. Dickstein K, Vardas PE, Auricchio A, et al. ESC Committee for Practice Guidelines. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace. 2010;12:1526-1536.
16. Giles PD, Rylance PB, Crothers DC. New results from the Modification of Diet in Renal Disease study: the importance of clinical outcomes in test strategies for early chronic kidney disease. QJM. 2008;101: 155-158.
17. McGavin CR, Artvinli M, Naoe H, et al. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978;2:241-243.
18. Rector T, Kubo S, Cohn J. Patients self-assessment of their congestive heart failure: content, reliability, validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail. 1987;3:198-209.
19. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351-357.
20. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11:1244-1247.
21. Tafreshi MJ, Weinacher AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy. 1999;19:974-978.
22. Di Francesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53: 399-406.
23. Franke J, Schmahl D, Lehrke S, et al. Adjuvant use of ivabradine in acute heart failure due to myocarditis. Case Report Med. 2011;2011:203690.
24. Colin O, Ghaleh B, Hittinger L et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282:H672YH679.
25. Simon L, Ghaleh B, Puybasset L et al. Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666.
26. Ceconi C, Freedman SB, Tardif JC, et al. BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;3:408-414.
27. Sarullo FM, Fazio G, Puccio D, et al. Impact of "off-label" use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;4: 349-355.
28. Tardif JC, O'Meara E, Komajda M, et al. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507-2515.
29. Post F, Münzel T. Ivabradine-a new therapeutic option for cardiogenic shock? Herz. 2009;34:224-229.
30. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favorable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550-555.
31. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-1679.
32. Kanorskii{dotless} SG, Tregubov VG, Pokrovskii{dotless} VM. Alternative therapy with ivabradine in patients with functional class III chronic heart failure. Kardiologiia. 2011;51:39-44.